CD8A and neoplasm: Ongoing studies, such as this one [19], investigate the use of CSF‐1R inhibitor PLX3397 in the early stages of tumor development to increase the effectiveness of ICIs by boosting the number of CD8+ T cells, modifying the TME, and promoting “hot tumor” characteristics.